More doubts swirl around Lumakras
With sales of the Amgen KRAS inhibitor flatlining an advisory panel is called to discuss its continued US approval.
A short-lived hold for Arcellx & Gilead
Less than two months after a patient death CART-ddBCMA’s pivotal multiple myeloma trial is cleared to restart.
US approval gives Jemperli a treatment niche
However, endometrial cancer remains a small use, and Jemperli has other ways to make a bigger splash.
